![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Week 96 Safety and Efficacy by Gender and Race Subgroups in Treatment-Naïve HIV-1-Infected Patients in the Phase III ECHO and THRIVE Trials
|
|
|
Reported by Jules Levin
Womens Intl Workshop Jan 9-10 2012 Bethesda MD
Claudia Martorell, MD, MPH, FACP,1 Esteban Ribera, MD,2 Sharon Walmsley, MSc, MD,3 Simon Vanveggel, MSc4 and Katia Boven, MD5
1The Research Institute, Springfield, MA, USA; 2Hospital Vall D'Hebron, Barcelona, Spain; 3University Health Network, Toronto, ON, Canada; 4Tibotec BVBA, Beerse, Belgium; 5Tibotec Inc., Titusville, NJ, USA
![women1.gif](../images/011112/011112-1/women1.gif)
![women2.gif](../images/011112/011112-1/women2.gif)
![women3.gif](../images/011112/011112-1/women3.gif)
![women4.gif](../images/011112/011112-1/women4.gif)
![women5.gif](../images/011112/011112-1/women5.gif)
![women6.gif](../images/011112/011112-1/women6.gif)
![women7.gif](../images/011112/011112-1/women7.gif)
![women8.gif](../images/011112/011112-1/women8.gif)
![women9.gif](../images/011112/011112-1/women9.gif)
![women10.gif](../images/011112/011112-1/women10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|